Strain Data Sheet

RBRC00915

Strain Information

Image
BRC No.RBRC00915
TypeTargeted Mutation CongenicCartagena
SpeciesMus musculus
Strain nameC.Cg-Irf9<tm1Ttg>/TtgRbrc
Former Common nameIRF-9 KO/BALB/c; BALB/cAJcl-Isgf3g<tm1>, IRF-9 Knockout mouse, BALB/c
H-2 Haplotype
ES Cell lineTT2 [(C57BL/6NCrlj x CBA/JNCrlj)F1]
Background strainBALB/cAJcl
Appearancealbino
Strain developmentDeveloped by Tadatsugu Taniguchi, Graduate School of Medicine and Faculty of Medicine, University of Tokyo. RBRC00915: Backcrossed to BALB/c (N8 generations), RBRC00916: Backcrossed to C57BL/6J (over N13 generations).
Strain descriptionIRF-9 gene knockout mice. Homozygous mutant mice exhibit lower serum interferon levels in response to viral infection. BALB/c background (RBRC00915), C57BL/6 background (RBRC00916).
Colony maintenanceHomozygote x Homozygote
References
Essential and non-redundant roles of p48 (ISGF3 gamma) and IRF-1 in both type I and type II interferon responses, as revealed by gene targeting studies.
Kimura T, Kadokawa Y, Harada H, Matsumoto M, Sato M, Kashiwazaki Y, Tarutani M, Tan R S, Takasugi T, Matsuyama T, Mak T W, Noguchi S, Taniguchi T
Genes Cells, 1, 115-124 (1996). 9078371

Health Report

Examination Date / Room / Rack

Gene

Gene SymbolGene NameChr.Allele SymbolAllele NameCommon NamesPromoterDiseases Related to This Gene
Irf9interferon regulatory factor 914Irf9targeted mutation 1, Tadatsugu Taniguchi
  • immunodeficiency 65, susceptibility to viral infections(MedGEN)
  • neoneomycin resistance gene (E. coli)14mouse phosphoglycerate kinase promoter (PGK promoter)
  • immunodeficiency 65, susceptibility to viral infections(MedGEN)
  • Phenotype

    Annotation by Mammalian phenotyhpe ontology
  • abnormal cytokine secretion(MP:0003009)

  • decreased bone mineral density(MP:0000063)

  • decreased interferon-alpha secretion(MP:0008563)

  • increased susceptibility to viral infection(MP:0002418)
  • Detailed phenotype data

    Ordering Information

    Donor DNAmouse IRF-9 genomic DNA, E. coli neo, mouse phosphoglycerate kinase promoter (PGK promoter)
    Research applicationImmunology and Inflammation Research
    Specific Term and ConditionsThe RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. The RECIPIENT shall inform the DEPOSITOR about the purpose of the use of the BIOLOGICAL RESOURCE and shall limit the use within the scope of the purpose described in this Agreement. The RECIPIENT shall inform the DEPOSITOR about the results obtained by the use of the BIOLOGICAL RESOURCE.
    DepositorTadatsugu Taniguchi (The University of Tokyo)
    Strain Statusan icon for Frozen embryosFrozen embryos
    Strain AvailabilityRecovered litters from cryopreserved embryos (2 to 4 months)
    Additional Info.Necessary documents for ordering:
    1. Approval form (Japanese / English)
    2. Order form (Japanese / English)
    3. Category I MTA: MTA for distribution with RIKEN BRC (Japanese / English)
    4. Acceptance of responsibility for living modified organism (Japanese / English)

    Genotyping protocol -PCR-
    Mouse of the Month May 2005

    BRC mice in Publications

    Thibault DL, Chu AD, Graham KL, Balboni I, Lee LY, Kohlmoos C, Landrigan A, Higgins JP, Tibshirani R, Utz PJ.
    IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice.
    J Clin Invest 118(4) 1417-26(2008) 18340381
    Martinet V, Tonon S, Torres D, Azouz A, Nguyen M, Kohler A, Flamand V, Mao CA, Klein WH, Leo O, Goriely S.
    Type I interferons regulate eomesodermin expression and the development of unconventional memory CD8(+) T cells.
    Nat Commun 6 7089(2015) 25953241